Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib dose-escalation study of GLPG0187 in advanced solid tumors
NL-OMON36388Phase 1Active, not recruiting
- Sponsor
- Galapagos NV
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GLPG-0187 in Nonhematologic neoplasms, sponsored by Galapagos NV. Primary endpoint: Dose-limiting toxicities by dose level. Started Mar 2011; status: active, not recruiting.
02
Drugs
GLPG-0187
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON36388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36388.